Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche: Luci e ombre

Translated title of the contribution: TNF alpha inhibitors for chronic inflammatory disorders: Lights and shadows

Giulia Gortani, Stefano Martelossi, Loredana Lepore

Research output: Contribution to journalArticlepeer-review

Abstract

The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.

Translated title of the contributionTNF alpha inhibitors for chronic inflammatory disorders: Lights and shadows
Original languageItalian
Pages (from-to)314-321
Number of pages8
JournalMedico e Bambino
Volume31
Issue number5
Publication statusPublished - May 2012

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'TNF alpha inhibitors for chronic inflammatory disorders: Lights and shadows'. Together they form a unique fingerprint.

Cite this